Apogee Therapeutics, Inc. (APGE)

Market Cap	1.92B
Revenue (ttm)	n/a
Net Income (ttm)	-182.15M
Shares Out	58.09M
EPS (ttm)	-3.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	347,966
Open	32.34
Previous Close	32.04
Day's Range	31.81 - 33.35
52-Week Range	26.20 - 63.50
Beta	n/a
Analysts	Strong Buy
Price Target	91.33 (+176.38%)
Earnings Date	May 12, 2025

About APGE

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications. The company develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of AD, which is in phase 2 clinical trials; and for the treatment of asthma and EoE which is in phase 1 clinical trial. It also develops APG279 that is in preclinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 14, 2023
• Employees: 196
• Stock Exchange: NASDAQ
• Ticker Symbol: APGE
• Website: https://www.apogeetherapeutics.com

Analyst Forecast

According to 4 analysts, the average rating for APGE stock is "Strong Buy." The 12-month stock price forecast is $91.33, which is an increase of 176.38% from the latest price.

Price Target

$91.33

(176.38% upside)

Analyst Consensus: Strong Buy